WINT גידול ברווח למניה בשנה הנוכחית Windtree

Windtree Therapeutics (WINT) develops unique cardiology treatments protected from generics. The current YoY EPS change on the GURU.Markets chart demonstrates volatility, with the metric equal to -36.70. High scaling potential via global patents coexists with severe risks, including an acute liquidity shortage and uncertainty regarding clinical trial outcomes, which calls into question the continued existence of the business.

Identifying fundamentally resilient assets requires an analysis of net income per share dynamics. This indicator measures the year-over-year percentage change in EPS, reflecting the actual return on capital while accounting for operating expenses and currency fluctuations. For Windtree Therapeutics (WINT), which relies on dilutive issuances due to the costs of cardiac drugs, the distribution of annual EPS changes on GURU.Markets reveals a critical dependence of returns on the capital structure.